Trimedic Therapeutics

Trimedic Therapeutics is a Canadian specialty pharmaceutical company focused on identifying and commercializing products that address unmet needs in acute and specialized care. Founded in 2019 and headquartered in the Greater Toronto Area, the company positions itself as a lean commercialization organization with regulatory, market access, sales, and distribution capabilities across Canada. Its lead and currently visible pharmaceutical product is Sibboran, a branded intravenous landiolol hydrochloride product approved and marketed in Canada for short-term ventricular rate control in supraventricular tachycardia, including atrial fibrillation and atrial flutter, in perioperative, postoperative, or other acute settings. The company appears to work primarily through in-licensing and distribution partnerships rather than internal drug discovery, including a notable collaboration with AOP Orphan Pharmaceuticals/AOP Health. Overall, Trimedic Therapeutics looks like a niche Canadian hospital-focused commercial pharma company rather than a traditional R&D-heavy biotech.